NEWS & EVENTS

Latest news and upcoming events

26 May 2021

Ysios Capital closes its third fund at €216 million ($260 million)

Upcoming events
  • Biospain 2021
    29 September – 1 October 2021,
    Pamplona, Spain

  • Biotech Europe Forum 2021
    7 October – 8 October 2021,
    Digital

  • Venture Capital Forum 2021
    13 October – 14 October 2021,
    Digital

OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function

OxThera AB, announces completion of its pivotal Phase 3 study and reports top line results.

Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors

Dr. Srivastava is currently the Chief Financial and Strategy Officer at eGenesis.

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

Published results show efficacy in both adrenomyeloneuropathy (AMN) and cerebral ALD (cALD) related models.

Ysios Capital closes its third fund at €216 million ($260 million)

To invest in up to 15 companies in Europe and the US, with eight investments already made alongside top US and European investors.

AELIX Therapeutics appoints Dr Melanie Rolli as CEO

Dr Rolli will support the company’s vision of positioning HTI vaccines for future functional cure strategies.

SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting

SparingVision has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06.

Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting

Compelling additional preclinical data further support therapeutic potential of gene therapy product to treat PFIC3.

SparingVision Presents Three Posters at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

SparingVision has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06.

Cytoki Pharma raises $45 million Series A financing

Ysios Capital joins 38 million euro Series A financing of Cytoki.

Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

AU-011 Demonstrates Targeted Cytotoxicity In Vitro and In Vivo in Both Breast and Lung Tumors.

Newsletter

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.